Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade.
The company’s stock has a 5-day price change of 2.86% and 13.72% over the past three months. GILD shares are trading 9.57% year to date (YTD), with the 12-month market performance up to 13.07% higher. It has a 12-month low price of $62.07 and touched a high of $89.74 over the same period. GILD has an average intraday trading volume of 6.12 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.04%, 7.38%, and 19.73% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Gilead Sciences, Inc. (NASDAQ: GILD) shares accounts for 84.85% of the company’s 1.25B shares outstanding.
It has a market capitalization of $110.51B and a beta (3y monthly) value of 0.20. The stock’s trailing 12-month PE ratio is 108.48, while the earnings-per-share (ttm) stands at $0.82. The company has a PEG of 17.25 and a Quick Ratio of 0.95 with the debt-to-equity ratio at 1.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.79% over the week and 1.57% over the month.
Earnings per share for the fiscal year are expected to decrease by -43.86%, and 92.60% over the next financial year. EPS should grow at an annualized rate of 6.29% over the next five years, compared to 1.55% over the past 5-year period.
Looking at the support for the GILD, a number of firms have released research notes about the stock. Leerink Partners stated their Outperform rating for the stock in a research note on October 21, 2024, with the firm’s price target at $74-$96. Bernstein coverage for the Gilead Sciences, Inc. (GILD) stock in a research note released on October 17, 2024 offered a Outperform rating with a price target of $105. Wells Fargo was of a view on October 07, 2024 that the stock is Overweight, while Raymond James gave the stock Outperform rating on July 08, 2024, issuing a price target of $93. Maxim Group on their part issued Buy rating on May 01, 2024.
